Servicio de Nefrología, Hospital Privado Universitario de Córdoba, Córdoba, Argentina. E-mail:
Instituto Universitario de Ciencias Biomédica de Córdoba (IUCBC), Córdoba, Argentina.
Medicina (B Aires). 2021;81(6):922-930.
The incidence of acute kidney injury (AKI) in hospitalized patients with COVID-19 is variable, being associated with worse outcomes. The objectives of the study were to evaluate the incidence, risk factors (considering demographic characteristics, comorbidities, initial clinical presentation and associated complications) and impact of AKI in subjects hospitalized for COVID-19 in two third-level hospitals in Córdoba, Argentina. A retrospective cohort study was conducted. We included 448 adults who were consecutively hospitalized for COVID-19 between March 3 and October 31, 2020 and were followed throughout the hospitalization. The incidence of AKI was 19% (n = 85; stage I = 43, stage II = 17, and stage III = 25, 18 required renal replacement therapy). In the multivariate analysis, the variables that were independently associated with AKI were: age (for every 10 years, adjusted odd ratio [95%CI] = 1.30 [1.04-1.63], p = 0.022), history of chronic kidney disease -CKD- (9.92 [4.52-21.77], p < 0.001), blood neutrophil count at admission -BNCA- (for every increase of 1000 BNCA, 1.09 [1.01-1.18], p = 0.037) and requirement for mechanical ventilation -MV- (6.69 [2.24-19.90], p = 0.001). AKI was associated with longer hospitalization, higher admission (63.5 vs. 29.7%; p < 0.001) and longer stay in the intensive care unit, a positive association with respiratory bacterial superinfection, sepsis, respiratory distress syndrome, MV requirement and mortality (mortality without AK I = 12.4% vs with AKI = 47.1%; stage I = 26%, stage II = 41% and stage III = 88%; p < 0.001). AKI was independently associated with higher mortality (3.32 [1.6-6.9], p = 0.001). In conclusion, the incidence of AKI in adults hospitalized for COVID-19 was 19% and had a clear impact on morbidity and mortality. The independent risk factors for AKI were: Age, CKD, BNCA and MV.
在因 COVID-19 住院的患者中,急性肾损伤 (AKI) 的发生率是不同的,且与更差的结局相关。本研究的目的是评估在阿根廷科尔多瓦的两家三级医院中,因 COVID-19 住院的患者 AKI 的发生率、风险因素(考虑人口统计学特征、合并症、初始临床表现和相关并发症)和影响。这是一项回顾性队列研究。我们纳入了 2020 年 3 月 3 日至 10 月 31 日期间连续因 COVID-19 住院的 448 名成年人,并在整个住院期间进行随访。AKI 的发生率为 19%(n=85;I 期=43,II 期=17,III 期=25,18 例需要肾脏替代治疗)。在多变量分析中,与 AKI 独立相关的变量为:年龄(每增加 10 岁,调整后的比值比[95%CI]为 1.30[1.04-1.63],p=0.022)、慢性肾脏病(CKD)史(9.92[4.52-21.77],p<0.001)、入院时血中性粒细胞计数(每增加 1000 个中性粒细胞,比值比为 1.09[1.01-1.18],p=0.037)和需要机械通气(MV)(6.69[2.24-19.90],p=0.001)。AKI 与住院时间延长、更高的入院率(63.5% vs. 29.7%;p<0.001)和 ICU 停留时间延长、与呼吸细菌合并感染、脓毒症、呼吸窘迫综合征、MV 需求和死亡率呈正相关(无 AKI 死亡率为 12.4%,AKI 死亡率为 47.1%;I 期为 26%,II 期为 41%,III 期为 88%;p<0.001)。AKI 与更高的死亡率独立相关(3.32[1.6-6.9],p=0.001)。总之,因 COVID-19 住院的成年人 AKI 的发生率为 19%,对发病率和死亡率有明显影响。AKI 的独立危险因素为:年龄、CKD、BNCA 和 MV。